Literature DB >> 8958260

In vivo immunoadsorption of antipig antibodies in baboons using a specific Gal(alpha)1-3Gal column.

S Taniguchi1, F A Neethling, E Y Korchagina, N Bovin, Y Ye, T Kobayashi, M Niekrasz, S Li, E Koren, R Oriol, D K Cooper.   

Abstract

The major role of anti-alphaGal antibodies in the hyperacute rejection of pig organs by humans and baboons has been clearly demonstrated. Spacered alpha-galactose disaccharide (Gal(alpha1)-3Gal) hapten was produced by chemical synthesis and covalently attached to a flexible, hydrophilic polymer (PAA), which in turn was covalently coupled to macroporous glass beads, forming an immunoadsorbent that is mechanically and chemically stable and can be sterilized. The extracorporeal immunoadsorption (EIA) of anti-alphaGal antibodies using this column has been investigated in vivo in 3 baboons. In Baboon 1 (which had hyperacutely rejected a pig heart transplant 4 months previously, was not splenectomized, and did not receive any pharmacologic immunosuppression) the levels of anti-alphaGal antibody and antipig IgM and IgG, as well as serum cytotoxicity, fell significantly after each of 3 EIAs but were not eliminated. Serum cytotoxicity, antipig immunoglobulin and anti-alphaGal antibody rose steeply within 24 hr of the final EIA, suggesting that the return of cytotoxicity was associated with anti-alphaGa1 antibody. In Baboons 2 and 3 (which were immunologically naive and splenectomized, and received triple drug immunosuppressive therapy) serum cytotoxicity was totally eliminated and anti-alphaGal antibody and antipig IgM and IgG levels were greatly reduced by courses of EIA. In Baboon 2, cytotoxicity and all antibody levels remained negligible for approximately one week after the final (fourth) daily EIA. In Baboon 3, cytotoxicity and antibody levels were maintained low by intermittent EIA (over a period of 13 days) for almost 3 weeks, although antipig IgM began to rebound 4 days after the final EIA. We conclude that, in an immunosuppressed, splenectomized baboon, repeated EIA using a specific alphaGal disaccharide column will reduce antipig and anti-alphaGal antibody levels and serum cytotoxicity significantly for several days. This reduction in cytotoxicity will almost certainly be sufficient to delay the hyperacute rejection of a transplanted pig organ, but further studies are required to investigate whether it will be sufficient to allow accommodation to develop.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958260     DOI: 10.1097/00007890-199611270-00001

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

Review 1.  Xenotransplantation: where are we today?

Authors:  M D Dooldeniya; A N Warrens
Journal:  J R Soc Med       Date:  2003-03       Impact factor: 5.344

2.  The living factory: in vivo production of N-acetyllactosamine containing carbohydrates in E. coli.

Authors:  E Bettler; E Samain; V Chazalet; C Bosso; A Heyraud; D H Joziasse; W W Wakarchuk; A Imberty; A R Geremia
Journal:  Glycoconj J       Date:  1999-03       Impact factor: 2.916

Review 3.  Current status of pig heart xenotransplantation.

Authors:  Muhammad M Mohiuddin; Bruno Reichart; Guerard W Byrne; Christopher G A McGregor
Journal:  Int J Surg       Date:  2015-08-28       Impact factor: 6.071

Review 4.  Antibody-mediated xenograft injury: mechanisms and protective strategies.

Authors:  Richard N Pierson
Journal:  Transpl Immunol       Date:  2009-04-17       Impact factor: 1.708

Review 5.  Overcoming the barriers to xenotransplantation: prospects for the future.

Authors:  Burcin Ekser; David K C Cooper
Journal:  Expert Rev Clin Immunol       Date:  2010-03       Impact factor: 4.473

Review 6.  Immunobiological barriers to xenotransplantation.

Authors:  David K C Cooper; Burcin Ekser; A Joseph Tector
Journal:  Int J Surg       Date:  2015-07-06       Impact factor: 6.071

Review 7.  Polyacrylamide-based glycoconjugates as tools in glycobiology.

Authors:  N V Bovin
Journal:  Glycoconj J       Date:  1998-05       Impact factor: 2.916

8.  Alpha-Galactosyl trisaccharide epitope: Modification of the 6-primary positions and recognition by human anti-alphaGal antibody.

Authors:  Peter R Andreana; Przemyslaw Kowal; Adam J Janczuk; Peng George Wang
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

Review 9.  Modifying the sugar icing on the transplantation cake.

Authors:  David K C Cooper
Journal:  Glycobiology       Date:  2016-03-01       Impact factor: 4.313

10.  Application of cyclophosphamide-induced tolerance in alpha1,3-galactosyltransferase knockout mice presensitized with Gal alpha 1-3Gal beta-4-GlcNAc antigens.

Authors:  Tatsushi Onzuka; Ichiro Shimizu; Yukihiro Tomita; Toshiro Iwai; Shinji Okano; Ryuji Tominaga
Journal:  Surg Today       Date:  2008-08-28       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.